Compare NATR & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NATR | ARMP |
|---|---|---|
| Founded | 1972 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 478.5M | 383.7M |
| IPO Year | 1995 | 1996 |
| Metric | NATR | ARMP |
|---|---|---|
| Price | $26.79 | $9.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $28.33 | $15.00 |
| AVG Volume (30 Days) | ★ 64.9K | 63.7K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 165.00 | N/A |
| EPS | ★ 1.06 | N/A |
| Revenue | ★ $480,144,000.00 | N/A |
| Revenue This Year | $7.76 | N/A |
| Revenue Next Year | $4.82 | N/A |
| P/E Ratio | $25.70 | ★ N/A |
| Revenue Growth | ★ 5.67 | N/A |
| 52 Week Low | $12.24 | $1.17 |
| 52 Week High | $28.14 | $14.98 |
| Indicator | NATR | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 53.71 | 40.04 |
| Support Level | $25.91 | $5.14 |
| Resistance Level | $26.96 | $12.11 |
| Average True Range (ATR) | 0.81 | 1.60 |
| MACD | -0.03 | -0.49 |
| Stochastic Oscillator | 38.08 | 0.00 |
Natures Sunshine Products Inc is a natural health and wellness company mainly engaged in the manufacturing and direct selling of nutritional and personal care products. The following Companies' product lines include: General health: Assorted health products related to blood sugar, bone health, cellular health, etc. Immune: offer products that support and strengthen the human immune system, Cardiovascular: Ingredients to give the cardiovascular system optimum support. Digestive: regulates intestinal and digestive functions, Personal care: personal care products for external use, and Weight management: to simplify the weight management process by providing healthy meal replacements. Business segment: Asia, Europe, North America, Latin America, and Other. The majority of revenue is from Asia.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.